Every Form 4 that Wellgistics Health Inc. (WGRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow WGRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WGRX filings page.
Wellgistics Health director Surendra K. Ajjarapu exercised warrants to acquire 100,000 shares of Common Stock at $0.005 per share on June 22, 2026. The warrants had been issued on March 31, 2026 in lieu of cash compensation. Following the issuer’s reverse stock split effective May 26, 2026 and this warrant conversion, Ajjarapu directly holds 257,645 shares of Common Stock, and the exercised warrant position is reduced to zero.
Wellgistics Health, Inc. Chief Executive Officer Prashant Patel exercised compensation-related warrants into common stock. On June 22, 2026, he exercised warrants covering 100,000 shares of common stock at an exercise price of $0.005 per share, converting them into common shares.
The warrants were originally issued to him on March 31, 2026 in lieu of cash compensation. Following a reverse stock split effective May 26, 2026 and this warrant conversion, Patel now directly holds a total of 282,365 shares of Wellgistics common stock.
Wellgistics Health, Inc. reported that Chief Executive Officer Prashant Patel received a large equity compensation package. On March 31, 2026, he was granted 5,000,000 shares of common stock at an indicated value of $0.20 per share, bringing his direct holdings to 9,118,247 common shares after the award. On the same date, he also received 5,000,000 warrants to purchase common stock with an exercise price of $0.0001 per share, exercisable from March 31, 2026 and expiring on March 31, 2031. Both the shares and the warrants were issued as compensation for his service and were granted in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Wellgistics Health, Inc. director Surendra K. Ajjarapu received a large equity compensation package. On March 31, he was granted 5,000,000 shares of common stock at $0.20 per share as compensation for his service, bringing his direct holdings to 7,882,247 shares.
He was also granted 5,000,000 warrants to purchase common stock with a $0.0001 exercise price, exercisable from March 31 and expiring on March 31, 2031. Both the shares and warrants were issued as compensation in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Wellgistics Health, Inc. reported that Chief Executive Officer Prashant Patel received significant equity compensation. On March 31, 2026, he was granted 5,000,000 shares of common stock at a stated value of $0.20 per share, increasing his direct holdings to 9,118,247 shares.
On the same date, he also received 5,000,000 warrants to purchase common stock with a $0.01 exercise price, expiring on March 31, 2031. The filing notes both the shares and warrants were issued as compensation for his service in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Wellgistics Health, Inc. director Surendra K. Ajjarapu received a large equity compensation package. On March 31, 2026, he was granted 5,000,000 shares of common stock at a stated value of $0.20 per share, bringing his direct holdings to 7,882,247 shares.
He was also granted 5,000,000 warrants to purchase common stock at an exercise price of $0.01 per share, expiring on March 31, 2031. The footnotes state both the shares and warrants were issued as compensation for his service in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933.